Skip to Content

Case Overview

Status:Status:Investigating
Company Name:Company Name:Biodesix, Inc.
Ticker:Ticker:BDSX
Related Attorneys:Lead Attorneys:Thomas W. Elrod
Related Practices:Related Practices:Securities
On November 5, 2026, Biodesix announced its third quarter 2026 financial results, reporting third quarter revenue of $24.0 million, below analyst expectations, and reducing its full-year 2026 revenue guidance to $101 million to $103 million from its prior guidance of $108 million to $114 million. Kinross CEO Scott Hutton stated that “execution and timing challenges,” specifically “fewer contributing sales representatives than planned, greater-than-anticipated seasonality in primary care and customer-delayed start of several development services projects,” led to quarterly results that “did not meet our expectations.” Hutton further explained the Company averaged 101 sales representatives during the quarter, below the Company’s second quarter average, due to higher turnover and a hiring pace that did not keep up with attrition and planned growth. Hutton stated, “As a result, a greater portion of our commercial effort was focused on maintaining existing accounts, reducing our capacity to acquire new ordering physicians.” On this news, the price of Biodesix shares declined by $11.31 per share, or approximately 57%, from $19.84 per share on November 5, 2026 to close at $8.53 on November 6, 2026.

Contact Us About This Case

You may share a link to this page on any of the sites listed below or send link via email: